- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lifeline begins First Warning trials
Breast cancer detection firm Lifeline BioTechnologies announced last month that it has received clearance to proceed with a 1200-women clinical trial for the company’s work-in-progress First Warning system.The multicenter study will be conducted in
Breast cancer detection firm Lifeline BioTechnologies announced last month that it has received clearance to proceed with a 1200-women clinical trial for the companys work-in-progress First Warning system.
The multicenter study will be conducted in Buenos Aires and La Plata, Argentina, under the guidance of Dr. Martin Laguens. Lifeline selected the sites because of the large number of unscreened female patients available for study through government medical programs. The three-part protocol will include women referred to breast clinics for existing problems, women recommended for surgical biopsy, and women who have never been screened.
Reno, NV-based Lifeline is developing First Warning as an early-detection, nonimaging breast cancer system for women considered too young for x-ray mammography. The system measures minute temperature changes in breast tissue over a 24 to 36-hour period with leads attached to the skin and a monitor that records data (SCAN 10/28/98). Lifeline hopes to file an application with the Food and Drug Administration next year for use of the product in detecting breast cancer, according to the company.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
